14 results about "Systolic function" patented technology

The invention discloses a left auricle plugging device provided with a real-time atrial pressure monitoring chip, and particularly relates to the technical field of left auricle plugging, the left auricle plugging device comprises a plugging device body and a connector, the top end of the connector is provided with a signal supply module, and the signal supply module is located in the plugging device body; according to the left atrial appendage plugging device, after the inductor in the nut generates a voltage signal, the signal can be transmitted to the low-noise operational amplifier and amplified, meanwhile, the electromagnetic interference between the noise of a circuit and the outside world is restrained, and the plugging device can be used for plugging the left atrial appendage of the left atrial appendage of the left atrial appendage. The physical deformation is converted into corresponding electric signals, the electric signals are transmitted to an in-vitro receiving terminal through an antenna, and a doctor can indirectly judge the recovery condition of the atrial contraction function of the patient according to the pressure signal trend.

The invention discloses a coronary artery hemodynamic information prediction method, device and equipment, a medium and a product, and relates to the field of biomechanics, and the method comprises the steps: obtaining clinical data, and segmenting the clinical data to obtain a coronary artery three-dimensional model and a heart three-dimensional model; constructing a human body blood circulation system lumped parameter model; determining a personalized human body blood circulation system lumped parameter model of the patient after assignment; constructing a 0-3-dimensional myocardial mechanical coupling model; constructing a first database; obtaining personalized systolic function parameters and diastolic function parameters of the patient based on the first mapping network; constructing a blood vessel 0-3-dimensional coupling model; constructing a second database; obtaining personalized coronary flow field information of the patient based on a second mapping network; the personalized coronary flow field information comprises a pressure field, a velocity field and concentration polarization characteristics of low-density lipoprotein on a blood vessel wall surface. Through network architecture innovation, the bottleneck of the model in the aspects of efficiency and personalization is solved, and the diagnosis precision of the coronary heart disease is improved.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

The invention relates to the technical field of biological medicines, in particular to application of indole-3-lactic acid in preparation of a medicine for treating heart failure. The application potential of indole-3-lactic acid (ILA) in treatment of ejection fraction retention type heart failure (HFpEF) is proposed and verified for the first time. By constructing a mouse HFpEF model, researches prove that ILA can significantly improve the diastolic function of the heart, specifically, the E / E'ratio is significantly reduced, and meanwhile, the left ventricular ejection fraction and the short-axis shortening rate are not affected, which indicates that the ILA effectively relieves the core pathological feature-diastolic dysfunction of the HFpEF on the basis of maintaining the systolic function of the heart.

The invention provides a simulated jellyfish-based plateau environment systolic function model, which comprises a jellyfish-shaped framework and a cardiac muscle tissue layer cultured on the jellyfish-shaped framework, and is used for simulating the systolic function of the heart through spontaneous or rhythmic systole; the pacing point and conduction system consists of a patterned myocardial cell layer and is used for generating and / or conducting an electric signal to stimulate rhythmic contraction / relaxation of a myocardial tissue layer; the balance weight is arranged at the bottom of the center of the jellyfish-shaped frame and used for enabling the gravity borne by the simulated jellyfish in the culture solution to be larger than the buoyancy borne by the simulated jellyfish. The invention also provides a simulated jellyfish-based plateau environment systolic function simulation and detection system, and the simulated jellyfish-based plateau environment systolic function model is used as a bionic simulator and is used for analyzing the motion state, tissue pathology and metabolism conditions of the bionic simulator in a body blood component culture solution in a simulated plateau environment. And evaluating the influence of the culture solution on the heart function.

The application discloses application of raloxifene or a pharmaceutical salt thereof in preparation of a medicine for treating sepsis cardiomyopathy, and simultaneously discloses application of a STAT3 protein Tyr705 site as a sepsis cardiomyopathy treatment target, and belongs to the technical field of biological medicines. The application proves through in-vivo and in-vitro experiments that raloxifene can effectively improve body temperature drop and left ventricular systolic function reduction related to sepsis cardiomyopathy, reduce myocardial inflammatory infiltration, relieve myocardial oxidative stress, mitochondrial dysfunction and energy metabolism disorder, and play a definite myocardial protection role by inhibiting phosphorylation activation of the STAT3 protein Tyr705 site in myocardial tissue and cells. The application provides a novel targeted treatment strategy and drug selection for sepsis cardiomyopathy, and has a good clinical transformation application prospect.

The invention discloses application of triethylene tetramine in preparation of a medicine for treating or preventing sepsis complications. Researches show that triethylene tetramine (TETA) can reduce the cardiac systolic function caused by lipopolysaccharide (LPS), and the damage to the mitochondrial structure of myocardial tissue is improved to a certain extent; the TETA also shows that the TETA can improve alveolar interval thickening, pulmonary edema, increase of protein concentration and lactic dehydrogenase activity in alveolar lavage fluid, formation of inflammasome, pyroptosis and the like caused by the LPS to a certain extent; the triethylene tetramine can inhibit expression of inflammatory factors in myocardial tissue and lung tissue, the effect of the triethylene tetramine in treatment or prevention of sepsis complications (sepsis cardiomyopathy and sepsis acute lung injury) is indicated, a new treatment choice is provided for sepsis patients, and the triethylene tetramine has important clinical application value.

The invention relates to an intelligent auxiliary system for left ventricular systolic function evaluation and application, and belongs to the technical field of medical instruments. The system comprises a data acquisition module, a standard evaluation module, a processing module and a data processing module, wherein the data acquisition module is used for acquiring DICOM (Digital Imaging and Communications in Medicine) format image data of a human heart left ventricle transthoracic echocardiogram; the data processing module comprises a left ventricular systolic function calculating device and is used for processing the left ventricular transthoracic ultrasonic image of the human heart and obtaining a left ventricular systolic function value; the computing device comprises a plurality of program codes, acquires image data of the TTE along with execution of the program codes, analyzes the ultrasound image data on the basis of pre-learned deep neural network model data, obtains a numerical value of the left ventricular systolic function, and guides formulation of a clinical treatment scheme.

The present disclosure features compositions and methods for modulating mammalian muscle contraction. The present disclosure also features compositions and methods for the treatment of a cardiac disease or disorder (e.g., a cardiac disorder involving abnormal force production and / or cessation in cardiac muscle, cardiac hypertrophy, reduced systolic function, reduced diastolic function, maladaptive hypertrophy, heart failure with preserved systolic function, diastolic heart failure, systolic heart failure, hypertensive heart disease, aortic and mitral valve disease, pulmonary valve disease, hypertrophic cardiomyopathy, post ischemic and post-infarction cardiac remodeling, or cardiac failure) in a subject. The methods involve administering flightin polypeptides and / or WYR polypeptides, or polynucleotides encoding the same, as described herein.

A system and method for prolonged organ preservation and real-time ex-vivo organ assessment. The organ perfusion and assessment system includes three components: A full cardiac output circuit, a resuscitation and low flow circuit, and an organ indexing stack to perform real-time hemodynamic ex-vivo organ assessment. A containment vessel maintains sterility and allows for complete echo-analysis. The slope of preload recruitable stroke work (PRSW) and other load-independent and load-dependent assays are used to stratify donor heart function. The best assessment of systolic function and therefore transplant suitability appears to be PRSW; the best systolic function is seen with full support of a donor heart. The best assessment of diastolic dysfunction appears to be Tau; the best diastolic function is also seen with full support of a donor organ. Load independent assessments appear to be highly repeatable and should identify currently discarded human donor hearts that are actually suitable for transplantation.